Women's Health

July 15, 2021

Given the low prevalence of anti-Sjögren's-syndrome-related antigen A (anti-SSA) and anti–Sjögren's-syndrome-related antigen B (anti-SSB) in women with rheumatoid arthritis who would like to conceive, intensive echocardiographic screening may not be necessary.

December 10, 2020

Positive ACPA status may not necessarily mean a greater likelihood of osteoporosis and fracture for rheumatoid arthritis patients, study shows.

November 25, 2020

Methotrexate can reduce inflammation and improve function in knees with osteoarthritis (OA), researchers report.

November 20, 2020

Over the course of this year there have been some pivotal studies on osteoporosis and women's health. We've published stories based on studies that explore the use of vitamin D and calcium supplementation and bone mineral density. We've featured a few studies that examine the effectiveness of bisphosphonates and the role of anabolic agents to to fight osteoporosis. Learn more about these and other studies in today's slideshow.

November 18, 2020

Osteoporosis therapeutic treatments should always be individualized, says Felicia Cosman, M.D., an endocrinologist with Columbia University College of Physicians and Surgeons in New York. Dr. Cosman is the author of a study recently presented at the American College of Rheumatology annual meeting in which she shared results from a study that explored treatment sequences with romosozumab before or after antiresorptive medication.

November 04, 2020

Beta blockers may slow the rate of bone loss that occurs as people age, a study published in JBMR Plus suggests.

November 04, 2020

Use of either oral or inhaled corticosteroids to manage asthma can increase the risk of osteoporosis and fragility fractures, suggest the findings of a large study published in Thorax.

October 07, 2020

In women 50 years of age or older, the risk of atypical femur fracture increased with longer bisphosphonate use, Asian ancestry, shorter height, higher weight and glucocorticoid use for one year or more, but this risk rapidly decreased after bisphosphonate discontinuation, according to a study recently published in New England Journal of Medicine.

September 16, 2020

Bisphosphonate use, especially for more than five years, is associated with an increased risk of atypical femoral fractures, but this risk falls considerably after discontinuation, according to a Nationwide Danish an analysis and review presented on September 13 at the American Society for Bone and Mineral Research (ASBMR) annual meeting which was held virtually.

September 14, 2020

Some evidence shows the combination of teriparatide and denosumab, followed by a single dose of zoledronate, may be an effective strategy in the long-term management of high-risk fragility fractures.